Could less chemo be better after stem cell transplants?
NCT ID NCT07193420
First seen Nov 01, 2025 · Last updated Jun 22, 2026 · Updated 45 times
Summary
This phase 3 trial tests whether a lower dose of the chemotherapy drug cyclophosphamide can reduce side effects after a half-matched stem cell transplant for blood cancers. The standard dose often causes complications, so researchers want to see if a lower dose works just as well. The study will follow 180 adults for two years to compare survival, relapse rates, and quality of life.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HSCT are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
Saint Antoine Hospital - Hematology Department
Paris, 75012, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Cyclophosphamide (a chemotherapy drug)
What this could lead to
If successful, a lower dose of cyclophosphamide could reduce side effects and improve survival without severe complications after stem cell transplants.
What could go wrong
This is an early-stage trial with only 180 participants, so results may not apply to everyone. Lowering the dose might also reduce its effectiveness in preventing graft-versus-host disease.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.